Blue Bird Corp Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Blue Bird Corporation on December 15, 2021. The filing discloses the entry into a material definitive agreement involving a private placement of equity securities and a concurrent change in the composition of the Board of Directors.
Key Financial Metrics and Transaction Details
The Company consummated a Subscription Agreement to raise capital through the issuance of Common Stock.
- Total Proceeds: $75 million aggregate purchase price.
- Share Price: $16.00 per share.
- Shares Issued: 4,687,500 total shares (3,564,549 to Coliseum Capital Partners, L.P. and 1,122,951 to Blackwell Partners LLC – Series A).
- Liquidity Impact: Immediate infusion of $75 million in cash proceeds.
- Debt and Margins: The filing text does not provide specific values for revenue, profit, operating margins, or existing debt levels.
Material Changes and Governance
As a result of the transaction, the size of the Board of Directors was increased to 10 members. Mr. Adam Gray, an affiliate of the Subscribers and Coliseum Capital Management, LLC, was appointed as a Class II director. The Subscribers were granted pre-emptive rights to maintain their pro rata ownership in future equity issuances under specific pricing conditions for a two-year period. Additionally, the Subscribers were added to the Company's Registration Rights Agreement, granting them customary shelf, demand, and piggyback registration rights.
Restrictions and Contingencies
The Subject Shares are subject to a 60-day lock-up period during which they cannot be transferred, disposed of, or monetized, except in compliance with the Securities Act of 1933. The pre-emptive rights granted to the Subscribers are contingent upon them holding at least 50% of the aggregate Subject Shares purchased.
Investor Verification Checklist
- Verify the exact number of shares outstanding post-transaction to calculate dilution impact.
- Review the full Subscription Agreement (Exhibit 10.1) for detailed terms regarding the pre-emptive rights and pricing adjustments.
- Confirm the use of proceeds as outlined in the accompanying press release (Exhibit 99.1).
- Assess the impact of the new director appointment on corporate governance and strategic direction.